SLS

13.6558.11%
AM

Angelos M. Stergiou

Founder, President, CEO & Director

Dr. Angelos M. Stergiou, MD, Sc.D. h.c., is the Founder, President, Chief Executive Officer and Director of SELLAS Life Sciences Group, Inc. (formerly known as SELLAS Life Sciences Group AG) (formerly, Sellas Inc.) since December 2012. Dr. Stergiou served as Vice President of Clinical Development & Medical Affairs at Anavex Life Sciences Corp. since February 2011. He served as Chairman of SELLAS Life Sciences Group, Inc. from 2012 to July 2016 and had been its Vice Chairman since July 2016 till December 2017. Dr. Stergiou has served on the Board of Directors of Cleara Biotech B.V., a biotech company located in the Netherlands, since January 2022. Dr. Stergiou has held international positions of increasing responsibility in the United States and Europe in pharma and biotechnology companies over the past few years including PAION AG, Accentia Biopharmaceuticals and BioVest International, Analytica International, as well as Clinical Research Organizations. Dr. Stergiou served as Vice President and Head of Drug Development at Accentia Biopharmaceuticals, Inc. from 2004 to 2008 and also served in the same capacity as well as Chief Medical Officer at its subsidiary Biovest International, Inc. during the same time. He has held specific roles ranging from Medical Director to Head of Clinical Research and Vice President of Product Development, Chief Medical Officer and Chief Operations Office with responsibility for medical affairs, clinical research and development, pharmacovigilance, clinical operations, project management, regulatory affairs, biostatistics and chemistry, manufacturing and controls (CMC). He has led and overseen research endeavors in all Phases of clinical development across many indications, including CNS and Alzheimer’s, cardiovascular, oncology, respiratory and autoimmune diseases and has a broad understanding of all aspects of clinical development and medical affairs. Dr. Stergiou has designed and implemented research projects in the United States, Canada, Australia, Japan and Europe. He has had numerous interactions with the FDA and European health authorities in addition to Australia and Japan. He has extensive medical and clinical development expertise and has been involved in progressing Alzheimer’s and numerous other clinical trials in prior roles. He also co-founded Genesis Life Sciences (Genesis Research) prior to founding Sellas, where he served as President and Chief Operating Officer from 2009 to 2011. He also led the Phase 3 development of a therapeutic cancer vaccine, BiovaxID, into completion which was presented at the American Society of Clinical Oncology plenary session in 2009 and also holds a patent on the technology. A prolific writer and respected editor, Dr. Stergiou has published papers in peer-reviewed literature and authored articles in journals in addition to being a reviewer/editor of peer-reviewed clinical journals. He has collaborated with the most internationally renowned academic institutions on clinical research endeavors including Beth Israel Deaconess Medical Center, MD Anderson Cancer Center, University of Pennsylvania, Cleveland Clinic, New York University, University of Heidelberg and the Mayo Clinic. Dr. Stergiou is a Member of the Board of Trustees at Kentucky Wesleyan College and a Fellow of the Royal Society of Medicine (UK – ID:00707077), he is an active Member of the World Medical Association, the American Academy of Pharmaceutical Physicians and Investigators, the Association of Clinical Research Professionals; member of the American Academy of Physicians in Clinical Researchand and the International Society for Pharmacoeconomics and Outcomes Research. A frequent guest lecturer/speaker for global clinical development and clinical research and regulatory matters, he has presented to audiences at conferences and at post-secondary institutions including Columbia University and numerous European universities. Dr. Stergiou holds an M.D. from the U.S. American Institute of Medicine and a Sc.D. h.c. from Kentucky Wesleyan College and received his Bachelor of Sciences degree from Kentucky Wesleyan College with a major in Pre-Medicine, Biology and Chemistry. He completed elective clinical work in interventional cardiology at the General Hospital Hagen (Germany) and cardiac surgery at the University of Cologne. He is fluent in English, German and Greek. Dr. Stergiou is Chairman of the Board of Cleara Biotech B.V.

Positions